Statement of Ownership (sc 13g)
June 01 2015 - 3:23PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION |
Washington, D.C. 20549 |
|
|
SCHEDULE 13G |
|
|
Under the Securities Exchange Act of 1934 |
|
(Amendment No. )* |
|
RXi Pharmaceticals
Corporation |
(Name of Issuer) |
|
Common Stock,
$0.0001 par value |
(Title of Class of Securities) |
|
74979C303 |
(CUSIP Number) |
|
May 27, 2015 |
(Date of event which requires filing of this statement) |
|
|
Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed: |
|
¨ |
Rule 13d-1(b) |
x |
Rule 13d-1(c) |
¨ |
Rule 13d-1(d) |
|
(Page 1 of 10 Pages) |
______________________________
*The remainder of this cover page shall
be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any
subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder
of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
CUSIP No. 74979C303 | 13G | Page 2 of 10 Pages |
1 |
NAMES OF REPORTING PERSONS
Empery Asset Management, LP |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) ¨
(b) ¨ |
3 |
SEC USE ONLY |
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
5 |
SOLE VOTING POWER
|
6 |
SHARED VOTING POWER
4,500,000 shares of Common Stock
2,250,000 shares of Common Stock
issuable upon exercise of Overallotment Common Stock Purchase Rights (See Item 4)*
2,250,000 shares of Common Stock
issuable upon exercise of Warrants (See Item 4)*
|
7 |
SOLE DISPOSITIVE POWER
|
8 |
SHARED DISPOSITIVE POWER
4,500,000 shares of Common Stock
2,250,000 shares of Common Stock
issuable upon exercise of Overallotment Common Stock Purchase Rights (See Item 4)*
2,250,000 shares of Common Stock
issuable upon exercise of Warrants (See Item 4)*
|
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,500,000 shares of Common Stock
2,250,000 shares of Common Stock
issuable upon exercise of Overallotment Common Stock Purchase Rights (See Item 4)*
2,250,000 shares of Common Stock
issuable upon exercise of Warrants (See Item 4)*
|
10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |
¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
7.86% (See Item 4)* |
12 |
TYPE OF REPORTING PERSON
PN |
|
|
|
|
|
* As more fully described in Item 4, each of the Overallotment Common
Stock Purchase Rights and the Warrants are subject to a 4.99% blocker and the percentage set forth in row (11) gives effect to
such blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares
of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blocker. Therefore,
the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is
less than the number of securities reported in rows (6), (8) and (9).
CUSIP No. 74979C303 | 13G | Page 3 of 10 Pages |
1 |
NAMES OF REPORTING PERSONS
Ryan M. Lane |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) ¨
(b) ¨ |
3 |
SEC USE ONLY |
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
United States |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
5 |
SOLE VOTING POWER
|
6 |
SHARED VOTING POWER
4,500,000 shares of Common Stock
2,250,000 shares of Common Stock
issuable upon exercise of Overallotment Common Stock Purchase Rights (See Item 4)*
2,250,000 shares of Common Stock
issuable upon exercise of Warrants (See Item 4)*
|
7 |
SOLE DISPOSITIVE POWER
|
8 |
SHARED DISPOSITIVE POWER
4,500,000 shares of Common Stock
2,250,000 shares of Common Stock
issuable upon exercise of Overallotment Common Stock Purchase Rights (See Item 4)*
2,250,000 shares of Common Stock
issuable upon exercise of Warrants (See Item 4)*
|
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,500,000 shares of Common Stock
2,250,000 shares of Common Stock
issuable upon exercise of Overallotment Common Stock Purchase Rights (See Item 4)*
2,250,000 shares of Common Stock
issuable upon exercise of Warrants (See Item 4)*
|
10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |
¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
7.86% (See Item 4)* |
12 |
TYPE OF REPORTING PERSON
IN |
|
|
|
|
|
* As more fully described in Item 4, each of the Overallotment Common
Stock Purchase Rights and the Warrants are subject to a 4.99% blocker and the percentage set forth in row (11) gives effect to
such blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares
of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blocker. Therefore,
the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is
less than the number of securities reported in rows (6), (8) and (9).
CUSIP No. 74979C303 | 13G | Page 4 of 10 Pages |
1 |
NAMES OF REPORTING PERSONS
Martin D. Hoe |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) ¨
(b) ¨ |
3 |
SEC USE ONLY |
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
United States |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
5 |
SOLE VOTING POWER
|
6 |
SHARED VOTING POWER
4,500,000 shares of Common Stock
2,250,000 shares of Common Stock
issuable upon exercise of Overallotment Common Stock Purchase Rights (See Item 4)*
2,250,000 shares of Common Stock
issuable upon exercise of Warrants (See Item 4)*
|
7 |
SOLE DISPOSITIVE POWER
|
8 |
SHARED DISPOSITIVE POWER
4,500,000 shares of Common Stock
2,250,000 shares of Common Stock
issuable upon exercise of Overallotment Common Stock Purchase Rights (See Item 4)*
2,250,000 shares of Common Stock
issuable upon exercise of Warrants (See Item 4)*
|
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,500,000 shares of Common Stock
2,250,000 shares of Common Stock
issuable upon exercise of Overallotment Common Stock Purchase Rights (See Item 4)*
2,250,000 shares of Common Stock
issuable upon exercise of Warrants (See Item 4)*
|
10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |
¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
7.86% (See Item 4)* |
12 |
TYPE OF REPORTING PERSON
IN |
|
|
|
|
|
* As more fully described in Item 4, each of the Overallotment Common
Stock Purchase Rights and the Warrants are subject to a 4.99% blocker and the percentage set forth in row (11) gives effect to
such blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares
of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blocker. Therefore,
the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is
less than the number of securities reported in rows (6), (8) and (9).
CUSIP No. 74979C303 | 13G | Page 5 of 10 Pages |
Item 1(a). |
NAME OF ISSUER: |
|
|
|
The name of the issuer is RXi Pharmaceuticals Corporation (the "Company"). |
Item 1(b). |
ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: |
|
|
|
The Company's principal executive offices are located at 257 Simarano Drive, Suite 101, Marlborough Massachusetts 01752. |
Item 2(a). |
NAME OF PERSON FILING: |
|
This statement is filed by the entities and persons listed below,
who are collectively referred to herein as "Reporting Persons," with respect to the shares of Common Stock (as
defined in Item 2(d) below) of the Company:
Investment Manager
(ii) Empery Asset Management, LP (the "Investment Manager"),
with respect to the shares of Common Stock held by, and underlying the Reported Purchase Rights and the Reported Warrants held
by, the funds to which the Investment Manager serves as investment manager, the "Empery Funds").
Reporting Individuals
(iii) Mr. Ryan M. Lane ("Mr. Lane"), with respect
to the shares of Common Stock held by, and underlying the Reported Purchase Rights and the Reported Warrants held by, the Empery
Funds.
(iv) Mr. Martin D. Hoe ("Mr. Hoe"), with respect
to the shares of Common Stock held by, and underlying the Reported Purchase Rights and the Reported Warrants held by, the Empery
Funds.
The Investment Manager serves as the investment manager
to each of the Empery Funds. Each of the Mr. Lane and Mr. Hoe (the “Reporting Individuals”) is a Managing Member
of Empery AM GP, LLC (the "General Partner"), the general partner of the Investment Manager. |
Item 2(b). |
ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: |
|
The address of the business office of each of the Reporting Persons
is:
1 Rockefeller Plaza, Suite 1205
New York, New York 10020 |
CUSIP No. 74979C303 | 13G | Page 6 of 10 Pages |
|
Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. |
Item 2(d). |
TITLE OF CLASS OF SECURITIES: |
|
|
|
Common Stock, $0.0001 par value (the "Common Stock") |
Item 2(e). |
CUSIP NUMBER: |
|
|
|
74979C303 |
Item 3. |
IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: |
|
(a) |
¨ |
Broker or dealer registered under Section 15 of the Act, |
|
(b) |
¨ |
Bank as defined in Section 3(a)(6) of the Act, |
|
(c) |
¨ |
Insurance Company as defined in Section 3(a)(19) of the Act, |
|
(d) |
¨ |
Investment Company registered under Section 8 of the Investment Company Act of 1940, |
|
(e) |
¨ |
Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940, |
|
(f) |
¨ |
Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F), |
|
(g) |
¨ |
Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G), |
|
(h) |
¨ |
Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act, |
|
(i) |
¨ |
Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940, |
|
(j) |
¨ |
A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); |
|
(k) |
¨ |
Group, in accordance with Rule 13d-1(b)(1)(ii)(K). |
|
If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J),
please
specify the type of institution:_________________________ |
CUSIP No. 74979C303 | 13G | Page 7 of 10 Pages |
|
|
The information as of the date of the event which requires filing
of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person
hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover
page for each Reporting Person is based on 57,221,598 shares of Common Stock issued and outstanding as of May 29, 2015, as represented
in the Prospectus filed with the Securities and Exchange Commission on May 29, 2015 pursuant to Rule 424(b)(4) of the Securities
Act of 1933, as amended.
Pursuant to the terms of the reported overallotment common stock
purchase rights (the "Reported Purchase Rights") and the reported warrants (the "Reported Warrants"),
the Reporting Persons cannot exercise any of the Reported Purchase Rights or the Reported Warrants to the extent the Reporting
Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding shares of Common Stock (the "Blockers"),
and the percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to the Blockers. Consequently,
as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to exercise any of
the Reported Purchase Rights or the Reported Warrants due to the Blockers.
The Investment Manager, which serves as the investment manager to
the Empery Funds, may be deemed to be the beneficial owner of all shares of Common Stock held by, and underlying the Reported Purchase
Rights and the Reported Warrants (subject, in each case, to the Blockers) held by, the Empery Funds. Each of the Reporting Individuals,
as Managing Members of the General Partner of the Investment Manager with the power to exercise investment discretion, may be deemed
to be the beneficial owner of all shares of Common Stock held by, and underlying the Reported Purchase Rights and the Reported
Warrants (subject, in each case, to the Blockers) held by, the Empery Funds. The foregoing should not be construed in and of itself
as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person.
Each of the Empery Funds and the Reporting Individuals hereby disclaim any beneficial ownership of any such shares of Common Stock. |
Item 5. |
OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS. |
|
Not applicable. |
Item 6. |
OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. |
|
Not applicable. |
Item 7. |
IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. |
|
Not applicable. |
Item 8. |
IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP. |
|
Not applicable. |
Item 9. |
NOTICE OF DISSOLUTION OF GROUP. |
|
Not applicable. |
CUSIP No. 74979C303 | 13G | Page 8 of 10 Pages |
|
Each of the Reporting Persons hereby makes the following certification: |
|
|
|
By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. |
CUSIP No. 74979C303 | 13G | Page 9 of 10 Pages |
SIGNATURES
After reasonable inquiry and to the best
of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.
DATED: June 1, 2015
|
|
|
|
|
EMPERY ASSET MANAGEMENT, LP |
|
|
|
By: EMPERY AM GP, LLC, its General Partner |
|
|
|
By: |
/s/ Ryan M. Lane |
|
Name: Ryan M. Lane |
|
Title: Managing Member |
|
|
|
/s/ Ryan M. Lane |
|
Ryan M. Lane |
|
|
|
/s/ Martin D. Hoe |
|
Martin D. Hoe |
CUSIP No. 74979C303 | 13G | Page 10 of 10 Pages |
EXHIBIT 1
JOINT ACQUISITION STATEMENT
PURSUANT TO RULE 13d-1(k)
The undersigned
acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent
amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing
additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such
amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible
for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason
to believe that such information is inaccurate.
DATED: June 1, 2015
|
|
|
|
|
EMPERY ASSET MANAGEMENT, LP |
|
|
|
By: EMPERY AM GP, LLC, its General Partner |
|
|
|
By: |
/s/ Ryan M. Lane |
|
Name: Ryan M. Lane |
|
Title: Managing Member |
|
|
|
/s/ Ryan M. Lane |
|
Ryan M. Lane |
|
|
|
/s/ Martin D. Hoe |
|
Martin D. Hoe |
RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Historical Stock Chart
From Aug 2024 to Sep 2024
RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Historical Stock Chart
From Sep 2023 to Sep 2024